

# Adult Congenital Heart Association

## Webinars Presents:

### Coping with Grief: Loss of a Loved One

Tuesday, April 24, 2018, 7 p.m. – 8 p.m. EDT

Presenter: Tracy Livecchi, LCSW

#### About the Webinar

Have you experienced the loss of a loved one or friend as the result of CHD or other causes? Do you know that grief is a normal and natural reaction to this loss? Do you know the difference between normal and complicated grief? This webinar will cover the basic knowledge of the grieving process, myths about the grief timeline, healthy coping strategies, when to seek professional help, and resources for continued self-help. Register today. You won't want to miss this important webinar.

**REGISTER NOW:** <http://bit.ly/2GGAFpF>

#### About the Presenter

Tracy Livecchi is fortunate enough to have been able to combine her life experience as a patient with congenital heart disease with her love of helping others. Tracy received her Master's degree in Social Work from Rutgers University in 1991 and she has been working as a psychotherapist in private practice since 1997. She has a diverse client background, with a special interest in working with adult congenital heart patients. From 2004-2008, she consulted for UCLA's Ahmanson's Adult Congenital Heart Disease Center and is currently the Mental Health Consultant for the Adult Congenital Heart Association.

#### About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit [www.achaheart.org](http://www.achaheart.org).

This webinar is made possible in part by sponsorship support provided by  
Actelion Pharmaceuticals US and Gilead Sciences, Inc.